Enanta Pharmaceuticals, Inc. (ENTA) News

Enanta Pharmaceuticals, Inc. (ENTA): $44.01

-1.96 (-4.26%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ENTA to Watchlist
Sign Up

Industry: Biotech


Ranked

of 395

in industry

Filter ENTA News Items

ENTA News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ENTA News Highlights

  • ENTA's 30 day story count now stands at 20.
  • Over the past 16 days, the trend for ENTA's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
  • DRUG, ESP and IR are the most mentioned tickers in articles about ENTA.

Latest ENTA News From Around the Web

Below are the latest news stories about Enanta Pharmaceuticals Inc that investors may wish to consider to help them evaluate ENTA as an investment opportunity.

Open Orphan client Enanta Pharmaceuticals confirms positive results from human challenge study - DirectorsTalk Interviews

Open Orphan client Enanta Pharmaceuticals confirms positive results from human challenge study

DirectorsTalk | February 17, 2022

Enanta Pharmaceuticals Announces Publication in The New England Journal of Medicine of Data from the Phase 2a Human Challenge Study of EDP-938 for the Treatment of Respiratory Syncytial Virus (RSV)

WATERTOWN, Mass., February 17, 2022--Enanta Pharmaceuticals Announces Publication in The New England Journal of Medicine of Data from the Phase 2a Human Challenge Study of EDP-938

Yahoo | February 17, 2022

Enanta Pharma Commences Dosing In Phase 1 COVID-19 Trial

Enanta Pharmaceuticals Inc (NASDAQ: ENTA ) has dosed the first subject in its Phase 1 trial of EDP-235 , a coronavirus 3CL protease inhibitor, specifically designed as a once-daily, oral treatment for COVID-19. The Company plans to report data from this study in Q2 of 2022, and, assuming positive findings, Enanta expects to advance EDP-235 to the … Full story available on Benzinga.com

Benzinga | February 16, 2022

Enanta begins dosing of oral COVID-19 therapy EDP-235 in phase 1 trial

Enanta Pharmaceuticals (ENTA) dosed the first person in its phase 1 trial of its oral COVID-19 therapy EDP-235.The phase 1 study will evaluate the EDP-235 in single ascending…

Seeking Alpha | February 16, 2022

Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-235, its Oral 3CL Protease Inhibitor Specifically Designed for the Treatment and Prevention of COVID-19

WATERTOWN, Mass., February 16, 2022--Enanta Doses First Subject in a Phase 1 Clinical Study of EDP-235, its Oral 3CL Protease Inhibitor Designed for the Treatment of COVID-19

Yahoo | February 16, 2022

Can Anyone Challenge Pfizer's Covid Dominance? Why These Biotechs Say Yes

Drug behemoth Pfizer was the first to launch a Covid antiviral pill — but a pack of small biotech stocks are already nipping at its heels.

Yahoo | February 11, 2022

Enanta Pharmaceuticals to Present at the SVB Leerink 11th Annual Global Healthcare Conference

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals to Present at the SVB Leerink 11th Annual Global Healthcare Conference

Business Wire | February 10, 2022

Enanta Pharmaceuticals, Inc. (ENTA) CEO Jay Luly on Q1 2022 Results - Earnings Call Transcript

Enanta Pharmaceuticals, Inc. (ENTA) Q1 2022 Earnings Conference Call February 08, 2022, 04:30 PM ET Company Participants Jennifer Viera - IR Jay Luly - President and CEO Paul Mellett - CFO Nathalie Adda - Chief Medical Officer Conference Call Participants Brian Abrahams - RBC Capital Markets Yasmeen Rahimi - Piper...

SA Transcripts on Seeking Alpha | February 9, 2022

Where Enanta Pharmaceuticals Stands With Analysts

Enanta Pharmaceuticals (NASDAQ: ENTA ) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 2 5 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 1 0 0 2M Ago 0 0 0 0 0 3M Ago 0 2 3 0 0 According to 7 analyst offering 12-month price targets in the last 3 months, Enanta Pharmaceuticals has an average price target of $86.43 with a high of $116.00 and a low of $68.00. Below is a summary of how these 7 analysts rated Enanta Pharmaceuticals over the past 3 months. The greater the number of … Full story available on Benzinga.com

Benzinga | February 9, 2022

Enanta Pharmaceuticals (ENTA) Q1 2022 Earnings Call Transcript

ENTA earnings call for the period ending December 31, 2021.

The Motley Fool | February 9, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5985 seconds.